ArticleScandinavian journal of immunology2025
The Nuclear Receptor Nurr1 Modulates the Expression and Activity of PPARγ in Human Pro-Inflammatory Macrophages.
Article in Scandinavian journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Nuclear Receptor Nurr1 Modulates the Expression and Activity of PPARγ in Human Pro-Inflammatory Macrophages.Scandinavian journal of immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Nurr1 is a member of the nuclear receptor family NR4A that modulates inflammation typically by inhibiting the NF-κB signalling pathway. In vitro, Nurr1 can interact with the peroxisome proliferator-activated receptor (PPAR)γ, as well as be recruited to the Pparg promoter in microglial cells; however, their functional relationship is not established. Here, we aimed to investigate the role of Nurr1 on PPARγ activity in human macrophages. Blood monocytes were cultured with GM-CSF or M-CSF to generate pro- (GM-MDMs) and anti-inflammatory (M-MDMs) macrophages, respectively. The protein levels of PPARγ and Nurr1 were elevated in GM-MDMs compared to M-MDMs, and their expression was positively correlated. PPARγ activation in GM-MDMs with the agonist rosiglitazone did not modify Nurr1 expression. However, Nurr1 activation with the agonist C-DIM12 increased PPARγ levels through protein stabilisation. Further, agonistic activation of Nurr1 decreased the proportion of PPARγ molecules phosphorylated at Ser84, which is a repressive mark for PPARγ transcriptional activity. Accordingly, exposure of GM-MDMs to C-DIM12 enhanced the expression of two PPARγ target genes induced by rosiglitazone, CD36 and PLIN2. Both PPARγ and Nurr1 agonists exhibited anti-inflammatory effects on LPS-stimulated GM-MDMs when administered alone, but C-DIM12 did not globally increase the effectiveness of rosiglitazone under that condition. These findings suggest that Nurr1 enhances PPARγ transcriptional activity, potentially through stabilising PPARγ protein levels and decreasing its repressive phosphorylation at Ser84. This novel mechanism highlights the role of Nurr1 in targeting not only inflammation but additional pathways regulated by PPARγ in macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.